Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Implantica CE Reflux , Ltd.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Implantica CE Reflux , Ltd.

Regulatory records
1
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 1 FDA record to the applicant name Implantica CE Reflux , Ltd.. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 20, 2026 to Aug 20, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LEI appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P250018, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: Sir Temi Zammit Bldg.S, Malta Life Sciences Park, San Gwann, SGN3000. Recorded on P250018, decision dated Aug 20, 2026.

Changes described in PMA records

P250018: RefluxStop Device and RefluxStop Deployment Tool

FDA’s recorded scope: REVEAL: A post-market study to assess safety and effectiveness of RefluxStop in the treatment of Gastroesophageal Reflux Disease (GERD) in general hospital practice New Enrollment PAS (Study Number RXI009, Version 7.0, dated July 30, 2026): This is a prospective, single-arm, multi-center study designed to evaluate the short- and long-term safety and effectiveness of RefluxStop in the treatment of GERD. The PAS will enroll a total of 200 patients with hiatal hernia size = 3 cm will be implanted with RefluxStop and followed for 5 years. Study participants will be enrolled at up to 10 clinical sites (minimum of 4 sites), with at least 50% of sites located in the United States and at least half of all procedures conducted at U.S. sites.The primary safety endpoint is the incidence of procedure- and device-related serious adverse device effects (SADEs), serious adverse events (SAEs) and device deficiencies (DDs) at 1 year. The rate of this composite endpoint will be compared to a performance goal (PG) of 16.2%. The primary effectiveness endpoint is pathologic acid in the lower esophagus measured by 24-hour pH monitoring (total percentage of time pH <4) at 1 yearSecondary study endpoints are as follows. Secondary safety endpoints include: incidence of procedure- and device-related SADEs, SAEs and DDs at all time points excluding at year 1, comprising month 6 as well as years 2 to 5; and incidence of procedure- or device-related Adverse Events (ADEs or AEs) at 6 months and annually thereafter up to 5 years. Secondary effectiveness endpoints include: subjects with <50% improvement of GERD-HRQL since baseline due to GERD; reduction in GERD-HRQL group score, measured at 6 months and years 1 to 5 compared to baseline; regular daily PPI usage due to GERD/acid reflux at 6 months and years 1 to 5; total percentage of time pH <4 measured by 24-hour pH monitoring at year 1; pathologic 24-hour pH monitoring and on-label device position at years 2 to 5; and incidence of inability to belch at 6 months and at years 1 to 5.The main 1-year safety and effectiveness endpoints will be analyzed as follows: The incidence of procedure- and device-related SADEs, SAEs and DDs at year 1 (primary safety endpoint) will be compared to a performance goal of <16.2%. Proportion of patients having pathologic 24-hour pH monitoring at year 1 (primary effectiveness endpoint) will be compared to a performance goal of 40%. Proportion of patients having <50% improvement of GERD-HRQL score at year 1 compared to baseline (secondary effectiveness endpoint) will be compared to a performance goal of <40%.For each of the three evaluations of 1-year endpoints, a descriptive summary will be provided on the observed rates compared to the defined performance goals.In addition, a long-term evaluation of device performance will be conducted by comparing 5-year endpoints in the PAS to long-term results following Nissen fundoplication based on literature.Descriptive analysis will be conducted on all other clinical endpoints.

Aug 20, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Devices & associated records

Product / regulatory recordCompanyPathwayDecision dateSource
Implantica CE Reflux , Ltd.PMA approvalAug 20, 2026FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.